Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)

BACKGROUND: The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M.G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., Rapisardi, S., Bordonaro, R., Zichi, C., De Vita, F., Di Maio, M., Parisi, A., Giampieri, R., Berardi, R., Lavacchi, D., Antonuzzo, L., Tamburini, E., Maiorano, B.A., Parrella, P., Latiano, T.P., Normanno, N., De Stefano, A., Avallone, A., Martini, G., Napolitano, S., Troiani, T., Martinelli, E., Ciardiello, F., Maiello, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588891/
https://www.ncbi.nlm.nih.gov/pubmed/35994791
http://dx.doi.org/10.1016/j.esmoop.2022.100567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588891/
https://www.ncbi.nlm.nih.gov/pubmed/35994791
http://dx.doi.org/10.1016/j.esmoop.2022.100567

Ejemplares similares